|
Women's Angiographic Vitamin and Estrogen Trial (WAVE) Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Women's Angiographic Vitamin and Estrogen Trial (WAVE) conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Women's Angiographic Vitamin and Estrogen Trial (WAVE) Clinical research trials and Women's Angiographic Vitamin and Estrogen Trial (WAVE) medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Women's Angiographic Vitamin and Estrogen Trial (WAVE). Women's Angiographic Vitamin and Estrogen Trial (WAVE) Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Women's Angiographic Vitamin and Estrogen Trial (WAVE) clinical trial. Subjects typically recieve the finest healthcare available for their Women's Angiographic Vitamin and Estrogen Trial (WAVE) condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "W" Clinical Trials Conditions > Women's Angiographic Vitamin and Estrogen Trial (WAVE)  Women's Angiographic Vitamin and Estrogen Trial (WAVE)
Women's Angiographic Vitamin and Estrogen Trial (WAVE)
For Condition: Cardiovascular Diseases,Coronary Arteriosclerosis,Coronary Disease,Heart Diseases,Myocardial Ischemia,Postmenopause
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To assess whether hormonal replacement therapy and/or antioxidant treatment would stabilize or inhibit progression, and induce regression of coronary plaques. The mechanisms by which these treatments modified atherosclerosis in women were also explored.
Details: BACKGROUND: Coronary artery disease is the leading cause of death in the United States, accounting for over 500,000 deaths each year. Although the onset of coronary artery disease is delayed in women, it is the single most important cause of death in women over the entire life span. Indeed, because more women than men survive to old age, mortality due to coronary artery disease for all ages combined is as great in women as in men. Furthermore, once they present with clinical evidence of coronary artery disease, women have a prognosis as poor as, or even worse, than that for men. In part, this may be due to late recognition of coronary artery disease in women, less intensive treatment of women, or a more adverse risk profile in women who develop coronary artery disease. The report of a recent Working Group on Angiographic Trials of Atherosclerosis Prevention notes that, compared to males, females who develop coronary artery disease, have various different characteristics which may affect the vascular response to lipid-altering interventions. These differences led the report to question whether the mechanisms and clinical benefits of lipid-altering agents may be different in men and women. It further noted that angiographic trials conducted to date have been based primarily upon the cholesterol-lowering treatments of diet or drugs and suggested that other approaches based upon the lipid hypothesis could profitably be tested and should be given the highest priority at this time; specifically recommended were trials of hormone replacement and antioxidant therapy in women. DESIGN NARRATIVE: Subjects were randomized into a 2 x 2 factorial trial of hormone replacement therapy and antioxidant therapy. Women were randomized into four treatment groups: both active hormone replacement and antioxidant; active hormone replacement therapy and antioxidant placebo; active antioxidant therapy and hormone replacement placebo; double placebo plus usual care. Hormone replacement therapy consisted of estrogen plus a progestin (PremPro) for all gynecologically intact women, and unopposed estrogen (Premarin) for women with hysterectomies. Antioxidants consisted of a combination of vitamin E and vitamin C. Angiographic change was a primary endpoint of this trial. The study was double-blind to the extent permitted by the interventions; however, it was fully-blinded with respect to outcome variables. Recruitment ended in August 1999. The mean duration of follow-up was approximately three years. The NHLBI awarded R01HL68397 in April 2001 as an ancillary study to WAVE. The study entitled "Modifying Oxidative Damage in WAVE" has its on site on this database.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Factorial Assignment
Minimum Age/Maximum Age: 38 Years/86 Years
Genders: Female
Protocol Entry Criteria: Postmenopausal women, up to age 86, with angiographically documented coronary artery disease of at least 15 percent, but no more than 75 percent occlusion.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JoelVerter, , George Washington University
Additional Information:
Study ID Numbers: 99;
Study Start Date: August 1996
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000555
Other Myocardial Ischemia Studies:
1. Cohort Study of Heart Rate Variability
2. Platelet Drug Trial in Coronary Disease Progression
3. Thrombolysis in Myocardial Ischemia Trial (TIMI III)
4. Open Study of enoxaparin vs. unfractionated heparin in patients with acute coronary syndromes
5. CVD Risk and Health in Postmenopausal Phytoestrogen Users
Related Studies:
Other Myocardial Ischemia Clinical Trials
Other Clinical Trials
Other Clinical Trials
Women's Angiographic Vitamin and Estrogen Trial (WAVE)
|
|
|
|
|
|
|
|
